Correction: Okomo-Adhiambo, M. et al. Neuraminidase Inhibitor Susceptibility Testing in Human Influenza Viruses: A Laboratory Surveillance Perspective. Viruses 2010, 2, 2269-2289

The authors would like to make the following corrections to their published paper:

There was an error in calculation of IC₅₀ fold changes for the NAI-resistant viruses reported in

Table 1. Reference viruses used as controls in the chemiluminescent NI Assay.

Strain Designation	Type/Subtype	NA Mutations (Genotype)	Oseltamivir Susceptibility	Mean IC50a ± SDb, nM (Fold Difference c)
				Oseltamivir	Zanamivir	Peramivir
A/Washington/10/2008	A (H1N1); Seasonal	WTd	Se	0.23±0.07 (1)	0.24±0.08 (1)	0.09±0.02 (1)
A/Florida/21/2008	A (H1N1); Seasonal	H275Y	Rf	94.82±27.04 (386412)	0.31±0.08 (1)	11.27±1.36 (134125)
A/Washington/01/2007	A (H3N2); Seasonal	WT	S	0.15±0.00 (1)	0.47±0.04 (1)	0.12±0.02 (1)
A/Texas/12/2007	A (H3N2); Seasonal	E119V	R	4.19±0.33 (3028)	0.51±0.05 (1)	0.14±0.02 (1)
B/Memphis/20/1996	B; Seasonal	WT	S	1.61±0.21 (1)	1.94±0.21 (1)	0.31±0.06 (1)
B/Memphis/20/1996	B; Seasonal	R152K	R	82.62±2.96 (5851)	26.35±13.59 (2214)	52.80±3.51 (176170)
A/California/07/2009	H1N1; Pandemic	WT	S	0.21±0.03 (1)	0.26±0.04 (1)	0.06±0.02 (1)
A/Texas/48/2009	H1N1; Pandemic	H275Y	R	79.94±0.06 (348381)	0.36±0.07 (1)	10.06±0.01 (164168)

^a Average of 3 independent assays. ^b SD, Standard Deviation of IC₅₀ values. ^c Fold difference in IC₅₀ values between mutant and wildtype viruses, by drug and virus type/subtype (IC₅₀ of mutant/IC₅₀ of wildtype virus). ^d WT, Wildtype. ^e S, Sensitive (Susceptible). ^f R, Resistant.

of the above-mentioned paper. The corrected values are marked in the updated Table 1 below.

We apologize for any inconvenience caused to the readers.